शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
CORONANSECORONA Remedies Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 2 Feb, 2026 · 18:25 IST

Q3 FY26 results: revenue up 15%, adjusted PAT up 23.7%

Exceptional itemProfit growth above 25%Results View source PDFExplain this filing

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+3.1%Reaction day
₹1460.00
prior close
₹1459.60
announcement price
After-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+3.7%-0.6% vs market
Pharmaceuticals peers, median of 157sector+2.6%+0.5% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.3
10m
-0.9
15m
-1.2
30m
-1.5
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+3.1+3.7-0.6+2.6+0.5
Next day
+0.8+5.1-4.3+2.6-1.9
2d
+5.1+4.0+1.1+1.6+3.5
3d
+5.5+3.2+2.3+1.1+4.4
4d
+11.5+5.9+5.6+2.9+8.6
5d
+11.7+6.9+4.8+3.1+8.6
1w
+10.6+5.9+4.7+2.5+8.0
15d
+9.3+2.1+7.3-0.7+10.0
1m
+6.2-3.5+9.6-2.7+8.8
2m
+1.9-4.2+6.2-4.8+6.8
3m
+18.8+10.9+7.9+4.0+14.9
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

CORONA Remedies Q3 FY26 standalone revenue grew 15% YoY to Rs.342.42 Cr; nine-month revenue rose 16.3% to Rs.1,050.09 Cr. Reported Q3 PAT dipped to Rs.41.25 Cr from Rs.44.77 Cr due to a one-time Rs.19.10 Cr charge for new Labour Codes. Adjusted PAT grew 23.7% in Q3 and 30.7% for nine months. EBITDA margin: 24.3% in Q3, 22.0% for nine months. The company listed on NSE and BSE on Dec 15, 2025 via IPO. Deloitte issued an unqualified review.

Likely market impact

Strong adjusted earnings growth supports story; one-time Labour Code charge drags reported Q3 PAT. Newly listed, watch execution.